<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0021">
 <label>21</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <string-name>
    <surname>Tavassoly</surname>
    <given-names>O</given-names>
   </string-name>, 
   <string-name>
    <surname>Safavi</surname>
    <given-names>F</given-names>
   </string-name>, 
   <string-name>
    <surname>Tavassoly</surname>
    <given-names>I.</given-names>
   </string-name>
  </person-group>
  <article-title>Heparin-binding peptides as novel therapies to stop SARS-CoV-2 cellular entry and infection</article-title>. 
  <source>Mol Pharmacol</source>. 
  <year>2020 Nov</year>;
  <volume>98</volume>(
  <issue>5</issue>):
  <fpage>612</fpage>â€“
  <lpage>619</lpage>.
  <pub-id pub-id-type="pmid">32913137</pub-id>
 </mixed-citation>
</ref>
